BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24693876)

  • 1. Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.
    Alexopoulou AN; Ho-Yen CM; Papalazarou V; Elia G; Jones JL; Hodivala-Dilke K
    BMC Cancer; 2014 Apr; 14():237. PubMed ID: 24693876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
    Beltjens F; Molly D; Bertaut A; Richard C; Desmoulins I; Loustalot C; Charon-Barra C; Courcet E; Bergeron A; Ladoire S; Jankowski C; Boidot R; Arnould L
    Int J Cancer; 2021 Jul; 149(1):200-213. PubMed ID: 33634878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray.
    Guo J; Gong G; Zhang B
    Tumour Biol; 2017 Jul; 39(7):1010428317713392. PubMed ID: 28671019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
    Christgen M; Geffers R; Kreipe H; Lehmann U
    Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
    Ugras S; Stempel M; Patil S; Morrow M
    Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
    Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
    Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMP-1 expression has an independent prognostic value in breast cancer.
    Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
    BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.